Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722650 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL29974522 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL29974782 | 0.83 | SLC6A4 (0.72) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL21722632 | 0.83 | SLC6A4 (0.72) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL21722633 | 0.83 | SLC6A4 (0.72) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL29447514 | 0.83 | SLC6A4 (0.72) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL21731163 | 0.83 | SLC6A4 (0.72) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL23521648 | 0.81 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21742901 | 0.81 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29974656 | 0.81 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115135644-B | Preparation method and crystal form of 3-aryloxy-3-five-membered heteroaryl-propylamine compound | 漳州片仔癀药业股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-112654616-B | 3-aryloxy-3-aryl-propylamines and application thereof | 漳州片仔癀药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| CN-115135644-A | Preparation method and crystal form of 3-aryloxy-3-pentabasic heteroaryl-propylamine compound | 漳州片仔癀药业股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| WO-2021160134-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL-PROPYLAMINE COMPOUND | 漳州片仔癀药业股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| EP-3838900-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838900-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2021-06-23 | — | — | EP | disclosed |
| CN-112654616-A | 3-aryloxy-3-aryl-propylamine compounds and application thereof | 漳州片仔癀药业股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| WO-2020035070-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | 漳州片仔癀药业股份有限公司 | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035070-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | 漳州片仔癀药业股份有限公司 | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119375-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | TRPV1, TRPA1, TRPC7 | SLC6A2 335/4885SLC6A4 172/4885SLC6A3 154/4885 |
| US-20230339920-A1 | PREPARATION METHOD FOR AND CRYSTAL FORM OF 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYLPROPYLAMINE COMPOUND | TRPV1, TRPC7, TRPC4 | SLC6A2 485/4885SLC6A4 94/4885SLC6A3 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.